Drug General Information (ID: DDIBUOYKM7)
Drug Name			Ozanimod		Drug Info		Human adenovirus e serotype 4 strain cl-68578 antigen		Drug Info
Drug Type		Small molecule				Vaccine
Therapeutic Class		Selective Immunosuppressants				Vaccine

Mechanism of Ozanimod-Human adenovirus e serotype 4 strain cl-68578 antigen Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Ozanimod				Human adenovirus e serotype 4 strain cl-68578 antigen
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Human adenovirus e serotype 4 strain cl-68578 antigen when combined with Ozanimod

Recommended Action
Management		The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment. If live attenuated vaccine immunizations are required, administration should occur at least 1 month prior to initiation of ozanimod. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ozanimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ozanimod. In patients who have recently been vaccinated, ozanimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur.

References
1	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.